Legal & General Group
TCRX icon

Legal & General Group’s TScan Therapeutics TCRX Stock Holding History

Legal & General Group’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,937
Closed -$5.43K – 3538
2025
Q1 		$5.43K Hold
3,937
– – ﹤0.01% 3264
2024
Q4 		$12K Hold
3,937
– – ﹤0.01% 3213
2024
Q3 		$19.6K Hold
3,937
– – ﹤0.01% 3058
2024
Q2 		$23K Buy
+3,937
New +$31K ﹤0.01% 2965

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Legal & General Group's TCRX Position: Q2 2025 in Review

Legal & General Group sold out of TScan Therapeutics (TCRX) in Q2 2025, closing a stake of 3,937 shares — an estimated $5.43K sold.

Legal & General Group first reported a position in TCRX in Q2 2024 and held it in 4 quarters. The position peaked at $23K in Q2 2024. 81 funds tracked by Wall St. Rank hold TCRX as of Q2 2025.

  • Legal & General Group reported no remaining TScan Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 3,937 TScan Therapeutics shares in Q2 2025, an estimated $5.43K.
  • Legal & General Group first reported a position in TScan Therapeutics in Q2 2024 and held it in 4 quarters.
  • Legal & General Group's TScan Therapeutics position peaked at $23K in Q2 2024.
  • 81 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.